[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Syndax Pharma 730 Third Avenue 9th Floor New York NY 10017 USA

www.syndax.com Employees: 298 P: 781-419-1400 F: 781-419-1420

Sector:

Medical

Description:

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.

Key Statistics

Overview:

Market Capitalization, $K 1,750,048
Enterprise Value, $K 1,959,028
Shares Outstanding, K 88,610
Float, K 84,357
% Float 95.20%
Short Interest, K 22,665
Short Float 25.58%
Days to Cover 18.58
Short Volume Ratio 0.55
% of Insider Shareholders 4.80%

Financials:

Annual Sales, $ 172,350 K
Annual Net Income, $ -285,420 K
Last Quarter Sales, $ 72,790 K
Last Quarter Net Income, $ -49,360 K
EBIT, $ -194,430 K
EBITDA, $ -204,950 K

Growth:

1-Year Return 24.05%
3-Year Return 5.61%
5-Year Return 16.93%
5-Year Revenue Growth 11,238.82%
5-Year Earnings Growth -75.94%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.55 on 08/04/26
Next Earnings Date 11/02/26
Earnings Per Share ttm -2.51
EPS Growth vs. Prev Qtr -14.58%
EPS Growth vs. Prev Year 33.73%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

SNDX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -372.94%
Return-on-Assets % -39.11%
Profit Margin % -165.60%
Debt/Equity 16.16
Price/Sales 10.68
Price/Cash Flow N/A
Price/Book 121.89
Book Value/Share 0.17
Interest Coverage -7.14
60-Month Beta 0.40
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.